Evidence map›Paper›PMID 41717258›Full record

ArticleRSC advances2026

Assisted evaluation of aniline's

Alaa Ahmed Mostafa, Soad S Abd El-Hay, Youstina Mekhail Metias, Mohamed Adel Said, Michael Gamal Fawzy

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alaa Ahmed MostafaPharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University Badr City Cairo 11829 Egypt alaaazzam30@gmail.com.ORCID https://orcid.org/0000-0002-2953-2460
Soad S Abd El-HayPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University Zagazig 44519 Egypt.ORCID https://orcid.org/0000-0003-1880-3699
Youstina Mekhail MetiasPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Zagazig University Zagazig 44519 Egypt.ORCID https://orcid.org/0000-0002-8127-3785
Mohamed Adel SaidPharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University Badr City Cairo 11829 Egypt alaaazzam30@gmail.com.ORCID https://orcid.org/0000-0002-7937-0084
Michael Gamal FawzyPharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University Badr City Cairo 11829 Egypt alaaazzam30@gmail.com.ORCID https://orcid.org/0000-0002-3996-4582

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The safety of pharmaceutical products is critically influenced by the presence of impurities and degradation products. Aniline (ANN) is a very toxic degradation product of atorvastatin (ATN), which can cause life-threatening diseases such as methemoglobinemia. For the first time, a comprehensive artificial intelligence study using molecular docking was applied to assess the ANN-induced methemoglobinemia by simulating different binding energies in different pockets of cytochrome P450 (CYP 1A2), revealing the most suitable position leading to toxicity. Moreover, environmental concerns have become increasingly important due to the toxic effects of the excessive use of organic solvents in chromatographic separation systems. Accordingly, greener surfactant systems comprising sodium dodecyl sulfate (SDS) and polyoxyethylene-23-lauryl ether (Brij-35) were employed as safer alternatives were used for the quantitation of ANN in the presence of salicylic acid as an aspirin impurity alongside four widely used cardiovascular drugs of aspirin (APN), atenolol (AEN), atorvastatin calcium (ATN), and losartan potassium (LSN) in pure form and pharmaceuticals. The method validation was done according to the International Conference for Harmonisation (ICH) guidelines with linearity ranges of (10-200), (5-140), (5-100), (5-130), (0.5-40), and (0.5-30) µg mL

Identifiers

PMID41717258
PMCPMC12915648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.